Forum Home | Log in | Signup | My Page | Rules | FAQ | Boards | Members | Search
« POPE 5 Home | Email msg. | Reply to msg. | Post new | Board info. Previous | Home | Next

Re: Stock Tip: KPTI 

By: Decomposed in POPE 5 | Recommend this post (1)
Mon, 04 Nov 19 5:38 PM | 58 view(s)
Boardmark this board | Pope 5 		Msg. 43817 of 62138
(This msg. is a reply to 35619 by Decomposed)
Jump:
Jump to board:
Jump to msg. #

KPTI is currently up 12.3% for the day, and 63% since first recommended here 4 months ago.
November 4, 2019

Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates

by
Zacks Equity Research,Zacks
finance.yahoo.com


Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates

Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.79 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 20.24%. A quarter ago, it was expected that this pharmaceutical company would post a loss of $0.97 per share when it actually produced a loss of $0.71, delivering a surprise of 26.80%.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

Karyopharm Therapeutics, which belongs to the Zacks Medical - Drugs industry, posted revenues of $13.15 million for the quarter ended September 2019, surpassing the Zacks Consensus Estimate by 718.23%. This compares to year-ago revenues of $0.24 million. The company has topped consensus revenue estimates just once over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Karyopharm Therapeutics shares have added about 24.9% since the beginning of the year versus the S&P 500's gain of 21.2%.

What's Next for Karyopharm Therapeutics?

While Karyopharm Therapeutics has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Karyopharm Therapeutics was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.83 on $3.91 million in revenues for the coming quarter and -$3.46 on $15.17 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the top 21% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

http://finance.yahoo.com/news/karyopharm-therapeutics-kpti-reports-q3-132501963.html




Avatar

Gold is $1,581/oz today. When it hits $2,000, it will be up 26.5%. Let's see how long that takes. - De 3/11/2013 - ANSWER: 7 Years, 5 Months


 - - - - -
View Replies (2) »



» You can also:
- - - - -
The above is a reply to the following message:
Stock Tip: KPTI
By: Decomposed in POPE 5
Fri, 05 Jul 19 8:47 PM 		Msg. 35619 of 62138

IMO, Karyopharm Therapeutics is a screaming deal at $8.65/share. The company just received FDA approval on its multiple myeloma drug, XPOVIA, and the drug is coming to market in a week. That's almost unheard of.

The company has a small market cap ($400 million), which means that the approval should impact it in a big way. The drug price will be $22,000 per month. Consider the 200,000 Americans who contract the disease each year and that it is almost always fatal. Then do the obvious math (200,000 Americans buying xpovia at $264,000 per year, Angie) keeping in mind what the company's current market cap is and that many of the world's multiple myeloma sufferers will probably start buying it too at some point. That will tell you why I'm excited about KPTI.

There are risks: Competing drugs do exist. Not many, imo. The FDA has only approved xpovia for use on patients who have already gone through several other regimens. So, xpovia will likely be limited to patients who are in their final year of life. (Remember that all who contract the disease reach that point eventually.) And the FDA states that it may withdraw its approval if future tests do not support the drug's efficacy. Politically, high priced drugs may come under attack, especially if a Democrat wins the White House.

I took my position at $8.95, so it's now a bit cheaper. I don't care. I'm in it for the long haul.

I don't buy many stocks anymore, mostly because my interest is ONLY in small-cap pharmaceuticals that get FDA approval on an important, high priced drug. KPTI meets all of my criteria.

« POPE 5 Home | Email msg. | Reply to msg. | Post new | Board info. Previous | Home | Next